Fig. 1.
![Fig. 1. TC phenotypes revealed by PAGE. / Serum (25 μL) saturated with 10 μL of radioactive B12(57Co-B12; 200mCi/mg, 1 μCi/mL [7.4 GBq/mg, 37 kBq/mL]; Amersham Pharmacia Biotech “CT2” diluted 1:5 N-saline) was incubated with 25 μL of neuraminidase (0.2 IU/mL) in 25 μL of buffer (0.05 M sodium acetate, 0.1% CaCl2, and 0.95% NaCl, pH 5.5) at 37°C for 30 minutes. Twenty-five μL was replaced with buffer (65% [wt/vol] sucrose) and bromophenol blue as an albumin- and front-marker. PAGE was performed in a 10% polyacrylamide gel (1.5 mm × 7.0 cm × 12.5 cm) with 3.5% concentrating top gel (1.5 cm high) and Tris-glycine electrode buffer at pH 8.3 and electrophoresed at 250 V.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/98/12/10.1182_blood.v98.12.3497/6/h82311910001.jpeg?Expires=1735552063&Signature=c3u9TYqziGRU2o2jCcpaPzTkh7y2qpBP4NSPJRRxJyfMG6OjLTXZqknU3E1FR00OaLPyTpp~ksryNfyUpFmZQb9BBsvg47DxvwWEvtsGg-1IXhw-x6P~RwY~R3TMa26pgog1VOIkll9BWmhIZBQQrcUxzJwjlzGHjMRmK2ePg-YSj45GPrdNJf1Kn2kfX60v6RFaAsh3DcYDNmMH~4rlciIkxswm14snk0j9ts5hpE8J7LkUmuxHmjmfUaVyj2sxnz16XlsQXGvfWkLGT2O9rybmf2i2IMtzwb~bUvJnuIQqGVf0tPdFQQHH8~2bJutlk2bcYdSXfe8G5cCnhTzeaA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TC phenotypes revealed by PAGE.
Serum (25 μL) saturated with 10 μL of radioactive B12(57Co-B12; 200mCi/mg, 1 μCi/mL [7.4 GBq/mg, 37 kBq/mL]; Amersham Pharmacia Biotech “CT2” diluted 1:5 N-saline) was incubated with 25 μL of neuraminidase (0.2 IU/mL) in 25 μL of buffer (0.05 M sodium acetate, 0.1% CaCl2, and 0.95% NaCl, pH 5.5) at 37°C for 30 minutes. Twenty-five μL was replaced with buffer (65% [wt/vol] sucrose) and bromophenol blue as an albumin- and front-marker. PAGE was performed in a 10% polyacrylamide gel (1.5 mm × 7.0 cm × 12.5 cm) with 3.5% concentrating top gel (1.5 cm high) and Tris-glycine electrode buffer at pH 8.3 and electrophoresed at 250 V.
